anaplastic thyroid cancer
Conditions
Interventions
Case series:DC immunocyte therapy
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-75 years; 2. postoperative pathology confirmed ATC diagnosis; 3. postoperative ATC patients, or patients undergoing adjuvant therapy (assisted radiotherapy, chemotherapy); 4. ECOG PS score 0-1 points; 5. qualified bone marrow function, liver and kidney function; 6. major organs function normally; 7. patients during childbearing age are required to contracept; 8. patient consensus. Written informed consent was provided prior to enrolling in the study and the patient was informed that they have rights to withdraw at any time during the study without any loss.
Exclusion criteria
Exclusion criteria: 1. combined with other malignant tumors; Chemotherapy contraindication; received radiotherapy at the target lesion and preoperative chemotherapy and immunotherapy; 2. anemia, Hb <90g / L; 3. poor vascular conditions, that can not meet the requirements of peripheral blood collection; 4. aberrant blood coagulation, or receiving thrombolytic or anticoagulant therapy; 5. has a blood-borne infectious disease, such as active hepatitis; 6. has a mental disorder; 7. severe concomitant disease, the estimated survival time is less than 1 years; 8. accompanied with other immune diseases or long-term use of immunosuppressants or hormones; 9. poor compliance and are difficult to follow up for a long time; 10. doctors think it is an unsuitable situation for patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunotoxicity;Immunogenicity;Treatment tolerance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Median survival;Disease Free Survival;metastasis; | — |
Countries
China
Contacts
Public ContactJingqiang Zhu
West China hospital
Outcome results
None listed